FNYS
INFI

First New York Securities’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

First New York Securities’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,000
Closed -$17K – 398
2013
Q3 		$17K Buy
+1,000
New +$19.1K 0.01% 317

Other funds holding INFI

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

First New York Securities's INFI Position: Q4 2013 in Review

First New York Securities sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2013, closing a stake of 1,000 shares — an estimated $17K sold.

First New York Securities first reported a position in INFI in Q3 2013 and held it in 1 quarter. The position peaked at $17K in Q3 2013. 104 funds tracked by Wall St. Rank hold INFI as of Q4 2013.

  • First New York Securities reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2013 after selling out during the quarter.
  • First New York Securities sold 1,000 Infinity Pharmaceuticals, Inc. shares in Q4 2013, an estimated $17K.
  • First New York Securities first reported a position in Infinity Pharmaceuticals, Inc. in Q3 2013 and held it in 1 quarter.
  • First New York Securities's Infinity Pharmaceuticals, Inc. position peaked at $17K in Q3 2013.
  • 104 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2013.

Based on First New York Securities's 13F filing for Q4 2013, filed 12 Feb 2014.